Form 4: Moderna President Sells Shares After Option Exercise

Moderna President Stephen Hoge executed a pre-planned sale of 160,009 shares of common stock following the exercise of stock options.

Summary

• Stephen Hoge, President of Moderna, Inc., engaged in transactions on February 23, 2026, under a Rule 10b5-1 trading plan adopted on November 13, 2025.
• Exercised stock options to acquire a total of 160,009 shares of common stock (111,679 shares and 48,330 shares) at an exercise price of $19.15 per share.
• Concurrently sold 160,009 shares of common stock at a price of $48.84 per share.
• Following these transactions, Hoge directly owns 1,457,427 shares of common stock.
• Indirectly owns 4,116 shares through Valhalla, LLC and 151,933 shares through a trust for the benefit of his spouse and children.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, it was pre-planned under a 10b5-1 plan and represents the monetization of vested options, which is a routine part of executive compensation.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned activity rather than a reactive sale.
• The sale price of $48.84 per share is significantly higher than the exercise price of $19.15, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though the context of option exercise often mitigates this.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding Moderna's future performance.

Management Comments

• The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as a means for executives to manage their equity compensation and diversify holdings in a compliant manner. These pre-scheduled sales typically do not reflect a change in management's outlook on the company's future prospects.

Comparison to Industry Standards

• This type of 'exercise and sell' transaction is a standard practice for executives across various industries, including biotech, to realize value from vested stock options while managing tax obligations.
• It aligns with common executive compensation practices where equity awards form a significant portion of total compensation.
• No specific comparable companies or projects are detailed in this filing, but the mechanism is widely observed among peers like Pfizer, BioNTech, and other large pharmaceutical companies.

Related Party Transactions

• Indirect ownership of 151,933 shares by a trust for the benefit of Dr. Hoge's spouse and children, with his spouse as a trustee. The reporting person disclaims Section 16 beneficial ownership except for pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be interpreted in various ways, but given it's a 10b5-1 plan, the impact is likely minimal as it's a routine compensation event. The net direct ownership change is zero, as shares acquired were immediately sold.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the execution of the 10b5-1 plan.

Key Dates

Recommendation

The filing details a routine insider transaction (exercise and sell) executed under a pre-arranged 10b5-1 plan. This type of transaction is common for executives monetizing vested equity compensation and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. The net change in direct beneficial ownership is zero.

Keywords

Moderna, MRNA, Stephen Hoge, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Biotechnology, Pharmaceuticals